BTIG analyst Julian Harrison maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $61.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison’s rating is based on several promising developments in Viridian Therapeutics’ pipeline. The completion of enrollment for the Phase 3 trials of VRDN-003, with its subcutaneous delivery method, is a significant milestone. This method is expected to be preferred by payors over intravenous options due to its convenience and cost-effectiveness. The anticipated data readout in the first half of 2026 is seen as de-risked, given the shared binding domains with veligrotug, which has shown strong efficacy and safety profiles in previous trials.
Additionally, the potential for a Breakthrough Therapy Designation for veligrotug could expedite its commercial availability, enhancing Viridian’s market position. The company’s strengthened intellectual property portfolio, with patents extending into the 2040s, further supports its long-term prospects. These factors, combined with the positive early data from VRDN-006, contribute to a favorable outlook for Viridian Therapeutics, justifying the Buy rating.
In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.